Company news

Zymeworks Inc. news in 2024

Zymeworks Inc.'s news releases, calls and decks from 2024, newest first.

View company

Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases

December 11, 2024

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

November 20, 2024

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

November 4, 2024

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

October 24, 2024

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

October 20, 2024

Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

October 9, 2024

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

September 17, 2024

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

September 2, 2024

Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results

July 31, 2024

Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock

July 31, 2024

Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

July 24, 2024

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate

July 21, 2024

Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

July 10, 2024

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

June 16, 2024

Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer

June 9, 2024

Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 1, 2024

Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

April 10, 2024

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

April 7, 2024

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

March 27, 2024

Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results

March 5, 2024

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting

March 4, 2024

Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call

February 13, 2024

Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors

February 7, 2024

Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025

January 3, 2024

Zymeworks Announces Additional Leadership Appointments

January 3, 2024

Calls in 2024

Decks in 2024